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Extended psychometric analysis was done using the factor analysis (Horn´s Parallel 
Analysis, Exploratory Factor Analysis) and Rasch analysis (RA, Rating Scale model) 
(Scale diagnostic, Validity, Reliability, Dimensionality and Local independence, 
Differential item functioning (DIF)). Results: Horn´s Parallel Analysis revealed one 
factor (loading factor > 0.40). RA showed a correct functioning of the rating categories 
of the scale. As for the item fit, only one item ‘It is easy to put on my device’ slightly 
underfitted the model (Outfit MSQ = 0.720, Infit MSQ = 0.650) and item ‘durability’ 
overfitted the model (Outfit MSQ = 1.378, Infit MSQ = 1.291). The study showed a 
few similar allocations of items along the logit scale, weight and fit was easy to 
endorse, whereas the look and comfort of the orthosis were difficult to agree with. 
No local dependency was detected. The targeting of item difficulty to the patient 
ability was good. Omega reliability value of CSD-Sk was 0.9 (polychoric Cronbach’s 
alpha level 0.9). No DIF was detected. ConClusions: Despite some limitations in 
terms of fit, psychometric properties of CSD-Sk are in line with previous analyses 
on the English, Swedish and Italian version of the tool.
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objeCtives: There is a lack of information about patient satisfaction with ortho-
paedic and prosthetic medical devices (OPMD). As they influence a compliance, 
tolerance and usefulness, it is important to obtain and valuate them. Also they 
can be useful for verifying and enhancing quality of OPMD, for improving quality 
management of health care provider as well as patient´s quality of life. Methods: 
Evaluation of patient satisfaction with OPMD was realised on the sample of patients 
with orthopaedic, neurologic and rheumatic diseases from Specialized Hospital 
for Orthopaedic Prosthetics in Bratislava, Bratislava Region, Slovak Republic. It 
was used a translated and cross-cultural adapted module of Client Satisfaction 
with Devices (CSD-Sk). The weight, fit, durability, pain, abrasion, putting on device, 
comfort and look of OPMD were evaluated. It was used a 4 point Likert scale with 
answers strongly agree, agree, disagree, strongly disagree. Results: Description of 
the study sample: age > 60 n%= 46.6, women n%= 75.1, high school educated patients 
n%= 56.0. The most patients had problems with lower limbs (42.5%), followed by 
spine (26.9%) and combination lower limbs and spine (25.9%). In case of type of dis-
eases the most patients had orthopaedic diseases (73.6%), combination orthopaedic 
and neurologic (13.5%) and neurologic diseases (7.3%). The most used OPMD were 
orthopaedic insoles (36.3%), waist belt (17.6%) and corset on the spine (5.2%). Overall 
patients were highly satisfied with OPMD. More than 50% responses on items were 
mostly strongly satisfied (63.2 – 51.8%), except durability (43.5%). The most negative 
responses were on fit (7.25%) and abrasion (6.22%). ConClusions: It was recorded 
a high satisfaction with OPMD among surveyed patients. Comparing our Resultsto 
the previous analysis in the world we can reveal higher level of patient satisfac-
tion. Hopefully we can conclude that Health Care Provider manages good quality of 
OPMD and these regulations may contribute to patient´s satisfying quality of life.
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objeCtives: For Sao Paulo, evaluate the clinical and economic impact of invest-
ments in programs to a) increase rate of timely hospital admissions (within 12 hours 
of symptom onset) for STEMI patients, and b) manage more STEMI patients with PCI 
versus alternative approaches (e.g. thrombolytics, no reperfusion). Methods: Data 
from the RBSCA Registry, DataSUS, and a private Sao Paulo hospital were modeled to 
quantify the impact from STEMI treatment scenarios year-over-year from 2013-2018. 
Model inputs included morbidity and mortality, labor productivity (average wage), 
direct costs, and burden of disease (measured by disability-adjusted life-years and 
value-of-statistical-life). Outcomes are calculated up to 1 year after initial MI for 
admitted versus non-admitted populations, the latter group being divided accord-
ing to treatment pathway: PCI, thrombolytics, no reperfusion, or CABG. Prospective 
outcomes through 2018 were modeled to calculate the value of continued invest-
ment in STEMI management Results: From 2013-2018, an investment of 1.2M 
USD (EKGs, education, ambulances) to increase STEMI utilization at current cath-
eterization laboratories would result in 2,031 lives saved and 22.0 million USD cost 
savings. ConClusions: Expenditures to improve STEMI management strategies 
in Sao Paulo showed favorable economic outcomes and mortality reduction when 
more patients were managed with PCI, suggesting that continued national invest-
ment in STEMI management could further improve these rates, with greater cost 
savings achieved.
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objetivos: Investigar entre as agências de Avaliação de Tecnologias em Saúde (ATS) 
a produção de estudos e a recomendação da utilização de PET-TC para o diagnóstico 
de metástases em pacientes com câncer de mama localmente avançado. Métodos: 
Foi realizada consulta à INAHTA (The International Network of Agencies for Health 
Technology Assessment) e à REDETSA (Red de Evaluación de Tecnologias en Salud 
de las Américas), por meio de correio eletrônico, questionando a realização de estu-
dos de ATS e de recomendações do PET-TC para o diagnóstico de metástases em 
pacientes que realizaram CO na avaliação pré-transplante com a de 69 pacientes 
que não a realizaram. ResultAdos: A análise do explante mostrou que, em ambos 
os grupos, CHC estava dentro dos critérios de Milão na maioria dos casos. Nenhuma 
das CO foi positiva para metástases. As taxas de sobrevida um e cinco anos pós-TxH 
foram de 81% e 69% nos que realizaram CO e de 78% e 62% nos que não a realizaram, 
respectivamente (p = 0,25). As taxas de recorrência, um e cinco anos após o TxH, em 
pacientes que realizaram CO foram de 4,8% e 10,7% e de 2,9% e 10,1% nos que não 
a realizaram, respectivamente (p = 0,46). ConClusões: A realização de CO gerou 
um gasto de US$ 27.582,914 e não apresentou uma relação de custo-efetividade.
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objeCtivos: Realizar una evaluación económica del sistema de terapia de radiación 
con rayos X vsacelerador lineal de alta energía en pacientes mexicanos, con cáncer 
de próstata de alto riesgo como tratamiento adjunto a terapia hormonal desde el 
punto de vista institucional. MetodologíAs: Se realizó una revisión sistemática 
identificándose que la radioterapia de intensidad modulada (IMRT) es usada para 
el tratamiento del cáncer como adición a una terapia hormonal, los aceleradores 
lineales de alta energía utilizados en el país realizan esta técnica, de igual forma el 
sistema de tratamiento de radiación con rayos, por lo cual la eficacia y seguridad 
es la misma para ambas intervenciones, por lo cual se realizó una minimización de 
costos, comparando el costo total de ambos dispositivos en un horizonte temporal 
de 10 años, el costo anual equivalente y el costo por sesión de quimioterapia, se 
realizó un análisis de sensibilidad univariado. ResultAdos: El sistema de terapia 
de radiación con rayos tuvo un costo de $132,969,600 y el acelerador lineal de alta 
tuvo un costo de $138,717,386.01, por lo cual hay un ahorro de $5,747,786.01 en los 
10 años de horizonte temporal. En los resultados del costo anual equivalente, el 
costo de sesión de radioterapia y el análisis de sensibilidad se obtienen resultados 
similares por lo tanto se observa que en todos los casos el sistema de terapia de 
radiación con rayos X es una alternativa costo ahorradora respecto a las opciones 
actualmente utilizadas en las instituciones de salud públicas. ConClusiones: El 
tratamiento de radioterapia con el sistema de terapia de radiación con rayos X, es 
una opción eficiente al compararlo con el acelerador lineal de alta energía ya que 
ambos dispositivos utilizan la misma técnica de radioterapia esto significa que 
tienen igual eficacia y seguridad, pero este nuevo dispositivo conlleva un menor 
costo de tratamiento.
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objeCtives: Cost-Utility analysis of Spinal Cord Stimulation Rechargeable 
(SCS-RC) vs. reoperation in the treatment of Failed Back Surgery Syndrome (FBSS) 
in Colombia. Methods: Through the adaptation of an economic model developed 
by Sigmatic Ltd t/a Abacus International for UK NICE submission, and previous 
data transferability analysis, a cost utility analysis was done comparing SCS-RC 
vs. Reoperation in patients with FBSS in Colombia. One short analytical deci-
sion tree and one long term Markov model were considered for model concep-
tualization of the health problem and treatment impact. The effectiveness and 
utility data was primarily based on data from the PROCESS trial combined with 
Colombian costing data. A 15 years horizon, a third party payer perspective and 3% 
discount rate for utilities and costs were assumed. The Health states considered, 
at annual cycles, were optimal pain relief, optimal pain relief with complications, 
sub-optimal pain relief, and sub-optimal pain relief with complications. Optimal 
pain relief occurs with a pain threshold of 50%. Incremental analysis along with 
univariate and probabilistic sensitivity analysis was done. Results: SCS-RC had 
an incremental costs of US$11.223 and 1,09 incremental QALYs, with an ICER of 
US$10.293 which is far lower than the US$24.300 GDP Percapita recommended 
by the WHO as threshold for development countries and a 62,2% probability of 
been cost-effective, when probabilistic analysis was ran. ConClusions: SCS-RC 
showed a 62,2% probability of been cost-effective when compared to Reoperation 
in patients with FBSS in Colombia.
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objeCtives: Each Provider of Health Care Services (PHCS) is according to the law, 
obligated to manage its quality of health care services. To fulfil this role, it has 
to use a tool that is validated and territorially adapted. Outcomes of the survey 
reveal the weaknesses and the corrective measures can be taken. Methods: The 
sample of patients with orthopaedic, neurologic and rheumatic diseases was from 
Specialized Hospital for Orthopaedic Prosthetics in Bratislava, Bratislava region, 
Slovak republic. It was made a translation and cross-cultural adaptation of CSD 
module into the Slovak language to evaluate weight, fit, durability, pain, abrasion, 
putting on device, comfort and look of orthosis and prosthesis medical devices. 
